MTOR and stomatitis: Comparisons among mTOR inhibitors revealed that patients receiving ridaforolimus experienced a significantly higher frequency of grade 3–4 mTOR inhibitor-associated stomatitis (mIAS) compared to patients receiving temsirolimus and everolimus (Mita et al., 2013b).